Lundbeck parks Alzheimer's drug hope as there is no evidence it works
Pharmaceutical firm Lundbeck still sees opportunities to treat Alzheimer’s, but believes patience is a virtue. ”Jumping blindly into this area without any clear evidence is really not good for business,” says Head of R&D Johan Luthman.
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen
Pharmaceutical firm Lundbeck is hoping to avoid the costly blunders of the past, and has therefore halted one of its drug hopes meant to treat the feared brain condition known as Alzheimer’s disease. At least for the time being.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck maps pandemic mental health impact on US residents
For subscribers
